At a glance
- Originator Nippon Hypox
- Developer Biotoxtech Co; Nippon Hypox
- Class Ethers; Hydroquinones; Small molecules
- Mechanism of Action Lipid peroxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver disorders
- Discontinued Atherosclerosis; Cancer; Systemic lupus erythematosus; Ulcerative colitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Liver-disorders(In volunteers) in South Korea (PO)
- 23 Mar 2016 Discontinued - Preclinical for Atherosclerosis in South Korea (PO)
- 23 Mar 2016 Discontinued - Preclinical for Systemic lupus erythematosus in South Korea (PO)